Alterity Therapeu…
AUAUDAlterity Therapeutics Ltd (US:PRNAF) — Biotechnology: Pharmaceutical Preparations. Numărul de burse pe care se tranzacționează acțiunile companiei: 2. Pe această pagină — preț și grafic, dividende, principalii deținători și istoricul numărului de acțiuni.
Despre companie
- Site web
- alteritytherapeutics.com
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sediu central
- MELBOURNE, Australia
- Director general
- Dr. David A. Stamler M.D.
- Angajați
- 11
- Acțiuni în circulație
- 218.5 mil. la 2026-06-30
- Free float
- 171.39 mil.
- Capitalizare de piață
- 81.28 mil. AUD
- Insideri
- 7.91%
- Investitori instituționali
- 17.98%
- Industrie (SIC)
- Pharmaceutical Preparations
Descriere
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Dividende
Nu s-au găsit plăți de dividende (verificat 08.10.2026). Probabil că societatea nu plătește dividende.
Știri din această săptămână
Încă nu există știri de pe site-ul companiei.
Cei mai mari acționari
| Deținător | Participație | Acțiuni | Data raportului |
|---|---|---|---|
| Meltzer (Brian Derek) (F… | ≈49.36% | 9.42 mil. | 2025-11-21 |
| Gozlan (Lawrence) (Direc… | ≈23.83% | 4.55 mil. | 2025-04-07 |
| Marks (Peter Vincent) (I… | ≈1.19% | 227 704 | 2026-08-31 |
| Twin Lakes Capital Manag… | 0.73% | 139 258 | 2026-06-30 |
| Morgan Stanley | 0.33% | 63 065 | 2026-06-30 |
| Greenleaf Trust | 0.32% | 62 000 | 2026-06-30 |
| HB Wealth Management, LL… | 0.31% | 58 460 | 2026-06-30 |
| Citadel Advisors Llc | 0.2% | 37 597 | 2026-06-30 |
| Kempler (Geoffrey Paul)… | ≈0.16% | 30 000 | 2025-11-21 |
| HRT Financial LP | 0.09% | 17 292 | 2026-06-30 |
| BNP Paribas Financial Ma… | 0.05% | 10 239 | 2026-06-30 |
| Gamma Investing LLC | 0.01% | 2 309 | 2026-06-30 |
| Rhumbline Advisers | 0.01% | 2 009 | 2026-06-30 |
| Acadian Asset Management… | 0.01% | 1 863 | 2026-06-30 |
| Fidelity Concord Street… | 0.01% | 1 155 | 2026-05-31 |
| Stamler (David) (Chief E… | — | 91.69 mil. | 2025-11-21 |
